Equities Analysts Offer Predictions for ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($2.72) for the year. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24).

A number of other research analysts have also recently weighed in on ARTV. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. HC Wainwright began coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics has a consensus rating of “Buy” and an average target price of $21.00.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $7.07 on Wednesday. Artiva Biotherapeutics has a 1 year low of $6.38 and a 1 year high of $17.31. The business has a fifty day simple moving average of $10.61.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. purchased a new position in Artiva Biotherapeutics in the third quarter valued at approximately $166,000. Franklin Resources Inc. acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $7,435,000. Barclays PLC purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth $304,000. Geode Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $4,774,000. Finally, Wellington Management Group LLP purchased a new position in Artiva Biotherapeutics in the third quarter valued at about $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.